TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28884989

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg daily for 12 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Open-label HCQ
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonist (LTRA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LTRA
Number of subjects: 60
Study: 25872950

Group type: EXPERIMENTAL
Intervention: Five weekly psychosocial interventions based on cognitive behavioral therapy (CBT) in combination with early palliative care (PC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early palliative care (PC) only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard oncologic care
Number of subjects: 0
Study: 24064164

Group type: EXPERIMENTAL
Intervention: Sealing material 1
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sealing material 2
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Sealing material 3
Number of subjects: 63

Group type: COMPARATOR
Intervention: Positive control (Group 4)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Negative control (Group 5)
Number of subjects: 63
Study: 21352559

Group type: EXPERIMENTAL
Intervention: Intra-operative local anaesthetic wound infiltration (60 mls of 0.25% bupivacaine with 1 in 200,000 adrenaline)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Intra-operative local anaesthetic wound infiltration
Number of subjects: 600
Study: 19763132

Group type: EXPERIMENTAL
Intervention: losartan/hydrochlorothiazide (L/HCTZ)
Number of subjects: 30

Group type: COMPARATOR
Intervention: losartan
Number of subjects: 30
Study: 17088140

Group type: EXPERIMENTAL
Intervention: Reslizumab at 3 mg/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reslizumab at 1 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Reslizumab (both dosages)
Number of subjects: 24
Study: 14758156

Group type: EXPERIMENTAL
Intervention: Proportional-assist ventilation (PAV)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Pressure-support ventilation (PSV)
Number of subjects: 7
Study: 11349183

Group type: EXPERIMENTAL
Intervention: 5-aminolevulinic acid
Number of subjects: 18

Group type: COMPARATOR
Intervention: benzoporphyrin-derivative monoacid ring
Number of subjects: 18
Study: 9154675

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 60
Study: 7967420

Group type: EXPERIMENTAL
Intervention: Treatment with 2 therapy courses for completely resected patients (branch R1)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Treatment with 4 therapy courses for patients with extra-abdominal localization or abdominal localization and LDH < 500 U/l (branch R2)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Treatment with 6 therapy courses for patients with abdominal localization and LDH >= 500 U/l (branch R3)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Intensification therapy for patients with incomplete response after 2 courses
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: CNS chemotherapy for CNS positive patients
Number of subjects: 212

Group type: COMPARATOR
Intervention: Comparison of pEFS for stage III abdominal disease and LDH >= 500 U/l
Number of subjects: 212
Study: 2889307

Group type: EXPERIMENTAL
Intervention: Idazoxan (20 mg po, three times a day)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 29681624

Group type: EXPERIMENTAL
Intervention: ROSE+
Number of subjects: 91

Group type: COMPARATOR
Intervention: ROSE-
Number of subjects: 91
Study: 26791187

Group type: EXPERIMENTAL
Intervention: Average-protein diets (15% of daily energy)
Number of subjects: 1092

Group type: COMPARATOR
Intervention: High-protein diets (25% of daily energy)
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 1092

Group type: EXPERIMENTAL
Intervention: Reduction in alanine and AAA tyrosine
Number of subjects: 1092
Study: 23116214

Group type: EXPERIMENTAL
Intervention: Unani formulation for ulcer healing
Number of subjects: 0
Study: 22771577

Group type: EXPERIMENTAL
Intervention: Navigation autonomy (content viewing order dictated based on stage of change)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of self-efficacy based testimonials (yes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proactive outreach (reminder emails)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decisional framework (prescriptive tone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Navigation autonomy (content viewing order not dictated by stage of change)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Use of self-efficacy based testimonials (no)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proactive outreach (no emails)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Decisional framework (motivational tone)
Number of subjects: 0
Study: 20733102

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 611

Group type: COMPARATOR
Intervention: MT
Number of subjects: 611
Study: 18608042

Group type: EXPERIMENTAL
Intervention: NT-proBNP measured at 0, 6, 12, 24, 36, 48, 72 and 96 hours following admission
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Baseline NT-proBNP measurement combined with one value taken between 24 and 96 hours (at 48 hours)
Number of subjects: 455
Study: 15970119

Group type: EXPERIMENTAL
Intervention: Multifaceted strategy (interactive educational meetings, local consensus process)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Passive dissemination strategy
Number of subjects: 153
Study: 12358335

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP) at doses of 50, 100, 200, or 500 microg x day(‐1) for eight weeks
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (BDP)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 65
Study: 10076146

Group type: EXPERIMENTAL
Intervention: Carbetocin (100 microg single dose)
Number of subjects: 694

Group type: COMPARATOR
Intervention: Oxytocin (standard 8-hour infusion)
Number of subjects: 694
Study: 7572651

Group type: EXPERIMENTAL
Intervention: Enalapril (1 mg intravenous, followed by oral therapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 43
Study: 2404556

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and heparin; 1 g 5-FU and 5000 U heparin daily for 7 days
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Urokinase; 10,000 U/hour for 24 hours
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group; surgery alone
Number of subjects: 304
Study: 6102865

Group type: EXPERIMENTAL
Intervention: Triclofos 70 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 0.02 mg kg‐1 + atropine 0.03 mg kg‐1
Number of subjects: 128

Group type: COMPARATOR
Intervention: All drugs (Triclofos, Diazepam, Flunitrazepam)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Triclofos 70 mg kg‐1
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Diazepam 0.25 mg kg‐1 and Flunitrazepam 0.02 mg kg‐1
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (Diazepam and Flunitrazepam)
Number of subjects: 128
Study: 31797310

Group type: EXPERIMENTAL
Intervention: Withholding ACEIs/ARBs
Number of subjects: 430

Group type: COMPARATOR
Intervention: Continue/start ACEIs/ARBs
Number of subjects: 430
Study: 29790913

Group type: EXPERIMENTAL
Intervention: Program 3 (most intensive ASP intervention)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Program 1 and 2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Program 3 vs Program 1 and 2
Number of subjects: 15
Study: 27415612

Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin (R group, n=26)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 10 mg rosuvastatin plus 2 g of ω-3 PUFAs (R + O group, n=24)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 50
Study: 24553480

Group type: EXPERIMENTAL
Intervention: New oral syrup containing paracetamol, phenylephrine hydrochloride, and guaifenesin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Reference oral liquid formulation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: New oral syrup
Number of subjects: 45
Study: 22442826

Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin (all doses)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 20980796

Group type: EXPERIMENTAL
Intervention: ZOSTAVAX® (zoster vaccine) administered concomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Number of subjects: 473

Group type: COMPARATOR
Intervention: PNEUMOVAX® 23 (pneumococcal vaccine) administered concomitantly with ZOSTAVAX®
Number of subjects: 473

Group type: COMPARATOR
Intervention: ZOSTAVAX® (zoster vaccine) administered nonconcomitantly with PNEUMOVAX® 23 (pneumococcal vaccine)
Number of subjects: 473
Study: 18508290

Group type: EXPERIMENTAL
Intervention: Satavaptan 5 mg once daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Satavaptan 12.5 mg once daily
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Satavaptan 25 mg once daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 16402635

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Famotidine
Number of subjects: 69
Study: 12635061

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg/kg/min (group 1, n = 23)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 2 microg/kg/min (group 2, n = 24)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil 3 microg/kg/min (group 3, n = 25)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.5%‐1% inspired) as a rescue anesthetic
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (2‐4 microg/kg/min) with isoflurane supplementation
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Remifentanil continuous infusions (1‐5 microg/kg/min)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Postoperative extubation criteria
Number of subjects: 72
Study: 10979946

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (400 microg/m(2), day on days 1‐90) with ATG, CyA, and DAN
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: ATG, CyA, DAN, and rhG‐CSF
Number of subjects: 119

Group type: COMPARATOR
Intervention: ATG, CyA, and DAN without rhG‐CSF
Number of subjects: 119
Study: 8774389

Group type: EXPERIMENTAL
Intervention: Controlled smoking
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nonsmoking
Number of subjects: 25
Study: 1734554

Group type: EXPERIMENTAL
Intervention: Tampons impregnated with tranexamic acid (TA), one tampon inserted
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tampons impregnated with tranexamic acid (TA), three tampons administered at 2-hourly intervals over 6 hours
Number of subjects: 19
Study: 6429705

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 100
Study: 30724356

Group type: EXPERIMENTAL
Intervention: Oral feeding
Number of subjects: 114

Group type: COMPARATOR
Intervention: Enteral feeding
Number of subjects: 114
Study: 30005608

Group type: EXPERIMENTAL
Intervention: Health Literacy Questionnaire (HLQ)
Number of subjects: 0
Study: 25818246

Group type: EXPERIMENTAL
Intervention: MDMA-assisted therapy
Number of subjects: 1133
Study: 25436480

Group type: EXPERIMENTAL
Intervention: Initial treatment for simple bone cysts (exact intervention details not provided)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Initial treatment for simple bone cysts
Number of subjects: 24
Study: 22437191

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus BMX 54 (vaginal application, one tablet once a week for 12 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 60
Study: 20507810

Group type: EXPERIMENTAL
Intervention: Unilateral slow-release fluoride glass devices
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilateral slow-release fluoride glass devices
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group A (five glass beads)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group B (five fluoride devices with plastic brackets facing down)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Group C (five fluoride devices with plastic brackets facing up)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 18327969

Group type: EXPERIMENTAL
Intervention: 1.8 mL of anesthetic solution
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 3.6 mL of anesthetic solution
Number of subjects: 32
Study: 15983312

Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 328

Group type: COMPARATOR
Intervention: Subcutaneous regular insulin
Number of subjects: 328
Study: 12797909

Group type: EXPERIMENTAL
Intervention: ACE-Inhibitors (group 1)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diuretics (group 2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Ca-Antagonists (group 3)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (group 0)
Number of subjects: 42
Study: 10334671

Group type: EXPERIMENTAL
Intervention: Normalization of haemoglobin (target 13.5-16.0 g/dl)
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Normalization of haemoglobin (target 13.0-14.0 g/dl)
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Target haematocrit 42%
Number of subjects: 1942

Group type: EXPERIMENTAL
Intervention: Increase haemoglobin to a mean of 12.5 g/dl
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Control group (target haemoglobin 9.5-10.5 g/dl)
Number of subjects: 1942

Group type: COMPARATOR
Intervention: Control group (target haematocrit 30%)
Number of subjects: 1942
Study: 8729309

Group type: COMPARATOR
Intervention: Buprenorphine (0.3 mg subcutaneous) on demand (group 1, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.3 mg)‐propacetamol (2 g)‐ketoprofen (100 mg) by intravenous route over 2 hours followed by an infusion of propacetamol (2 g) and ketoprofen (100 mg) at a constant rate over 22 hours (group 2, n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Continuous infusion of buprenorphine (0.3 mg), propacetamol (2 g) and ketoprofen (100 mg) over the same period (group 3, n = 20)
Number of subjects: 60
Study: 1877449

Group type: EXPERIMENTAL
Intervention: Simulated dual-chamber pacing (DDD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated single-chamber pacing (VVI)
Number of subjects: 0
Study: 6145288

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30310979

Group type: EXPERIMENTAL
Intervention: Whole Body Cryotherapy (WBC) - 3 and 4 min at -85 °C
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI) - 10 min at 10 °C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 24
Study: 29800066

Group type: EXPERIMENTAL
Intervention: Spanish-support intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: English-only intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Spanish-support control
Number of subjects: 61

Group type: COMPARATOR
Intervention: English-only control
Number of subjects: 61
Study: 27386642

Group type: EXPERIMENTAL
Intervention: Yiguanjian Decoction (YD) combined with Adefovir Dipivoxil Tablet (ADT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Adefovir Dipivoxil Tablet (ADT) alone
Number of subjects: 68
Study: 24268670

Group type: EXPERIMENTAL
Intervention: Targon FN
Number of subjects: 52

Group type: COMPARATOR
Intervention: SHS
Number of subjects: 52
Study: 19363197

Group type: EXPERIMENTAL
Intervention: Subjective frequency ratings from Group 1
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Subjective frequency ratings from Group 2
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Imageability ratings from Group 1
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Imageability ratings from Group 2
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Combined ratings from both groups
Number of subjects: 144
Study: 15850502

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 2861
Study: 12520748

Group type: EXPERIMENTAL
Intervention: MIP regimen (mitomycin + ifosfamid + cisplatin)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: TP regimen (Taxol + cisplatin)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: DP regimen (docetaxel + cisplatin)
Number of subjects: 92
Study: 9220875

Group type: EXPERIMENTAL
Intervention: Pain management strategies and medications at hospital admission
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Use of antiseptics vs cleansing solutions
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Use of non-recommended treatments for ulcers
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Pain control and ulcer management
Number of subjects: 959
Study: 8193690

Group type: EXPERIMENTAL
Intervention: PRP-D vaccine
Number of subjects: 125000

Group type: EXPERIMENTAL
Intervention: HBOC vaccine
Number of subjects: 125000
Study: 3812345

Group type: EXPERIMENTAL
Intervention: Lowest selenium quintile (< 105.0 micrograms/L)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (matched cohort members alive at the end of 1983)
Number of subjects: 10
Study: 30153780

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Histamine-2 Receptor Blockers (H2RB)
Number of subjects: 50
Study: 26909479

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU retinyl palmitate per day for 4 months)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 24552184

Group type: EXPERIMENTAL
Intervention: IN.PACT Amphirion™ paclitaxel drug-eluting balloon (IA-DEB)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Standard balloon angioplasty (PTA)
Number of subjects: 358
Study: 22681643

Group type: EXPERIMENTAL
Intervention: Urethral sparing intensity modulated radiation therapy (US‐IMRT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard intensity modulated radiation therapy (S‐IMRT)
Number of subjects: 16
Study: 20836856

Group type: EXPERIMENTAL
Intervention: Pedometer-based Internet mediated intervention
Number of subjects: 0
Study: 17667137

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac
Number of subjects: 90

Group type: COMPARATOR
Intervention: Oral mefenamic acid and intramuscular meperidine
Number of subjects: 90
Study: 15126522

Group type: EXPERIMENTAL
Intervention: 120 microg FSH-CTP
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 180 microg FSH-CTP
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 240 microg FSH-CTP
Number of subjects: 98

Group type: COMPARATOR
Intervention: 150 IU rFSH (control)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: FSH-CTP groups
Number of subjects: 98

Group type: COMPARATOR
Intervention: rFSH group (control)
Number of subjects: 98
Study: 11452896

Group type: EXPERIMENTAL
Intervention: 200 mg slow release dipyridamole (DP)
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: Combination of ASA plus DP
Number of subjects: 6602

Group type: EXPERIMENTAL
Intervention: 2 x 25 mg acetylsalicylic acid (ASA)
Number of subjects: 6602

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6602
Study: 9729596

Group type: EXPERIMENTAL
Intervention: 1,100 kcal exercise session
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1,300 kcal exercise session
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 1,500 kcal exercise session
Number of subjects: 11

Group type: COMPARATOR
Intervention: 800 kcal exercise session
Number of subjects: 11
Study: 7920874

Group type: EXPERIMENTAL
Intervention: Rehabilitation Centre group (RC group) - three-week in-patient weight reduction programme
Number of subjects: 52

Group type: COMPARATOR
Intervention: Health Centre group (HC group) - ten-week out-patient weight reduction course
Number of subjects: 52
Study: 3288723

Group type: EXPERIMENTAL
Intervention: High-dose pentobarbital
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control regimen without pentobarbital
Number of subjects: 73
Study: 31657275

Group type: EXPERIMENTAL
Intervention: High DCI content group (550 mg MYO + 300 mg DCI daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low DCI content group (550 mg MYO + 27.6 mg DCI daily)
Number of subjects: 11
Study: 30019528

Group type: EXPERIMENTAL
Intervention: dHACA (dehydrated human amnion and chorion allograft) applied weekly for up to 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: SOC (standard of care) alone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: dHACA (dehydrated human amnion and chorion allograft)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SOC (standard of care)
Number of subjects: 80
Study: 28526171

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) disc dressing
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB) disc dressing
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 101
Study: 25632150

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15